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The world is fighting the COVID-19 outbreak and health workers, including inflammatory bowel diseases
specialists, have been challenged to address the specific clinical issues of their patients. We hereby summarize
the current literature in the management of inflammatory bowel disease (IBD) patients during the COVID-19
pandemic era that support the rearrangement of our IBD unit and the clinical advice provided to our patients.
KEYWORDS: COVID-19; Inflammatory Bowel Disease; Coronavirus; Pandemic.
’ INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a viral respiratory
illness caused by the novel coronavirus 2019 (2019-nCoV)
which originated from bats (1). The 2019-nCoV is a single-
stranded RNA virus and was named by the World Health
Organization (WHO) as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) because of its similarity to
the virus causing severe acute respiratory syndrome. The
infection outbreak began in December 2019 in Wuhan, China
and rapidly spread throughout the world, including Brazil.
On March 11th, 2020, WHO declared COVID-19 as a global
pandemic. Now more than one million confirmed cases of
COVID-19 have been reported to the WHO, including more
than 50,000 deaths. In Brazil, as of April 4th, 2020, we have
confirmed 10,278 infected patients and 432 deaths, and the
numbers continue to increase.
COVID-19 is transmitted mainly through respiratory drop-
lets, aerosols, and through the conjunctiva (2). The clinical
spectrum of COVID-19 in adults ranges from asymptomatic
infection to severe pneumonia and fatal illness. The main
clinical symptoms include fever, cough, shortness of breath,
myalgia, and 10-20% of patients develop acute respiratory
distress syndrome after 8–14 days of the illness (3). Based on
data from more than 72,000 patients from China, 81% of the
patients were mildly affected, 14% had severe manifesta-
tions, and 5% were critically ill. No deaths occurred in
children younger than 9 years but the mortality rate ranged
from 8-15% in those aged older than 70 years (4). Risk factors
for severe illness were older age and pre-existing comorbid
conditions including cardiovascular disease, hypertension,
diabetes, chronic respiratory disease, and cancer. Children of
all ages appeared susceptible to COVID-19, but clinical
manifestations were less severe compared to those seen in
adults (5). Around 6% of children suffered severe disease and
life-threatening conditions, but these patients commonly had
a prior history of congenital or acquired disease or were
younger than 1 year (4,5).
Digestive symptoms are reported in nearly half of the
patients with COVID-19. Diarrhea and fever may be present
in addition to respiratory symptoms (6). Since SARS-CoV-2
RNA was detected in stool samples and other clinical
specimens, awareness has been raised regarding the manage-
ment of patients with pre-existing digestive diseases, such as
inflammatory bowel disease (IBD). Special attention was also
given to potential SARS-CoV-2 transmission via a fecal route
(7,8). Following viral infection, virus-specific RNA and
proteins are synthesized in the cytoplasm to assemble new
virions. The detection of viral RNA from feces 1 to 12 days
after being negative in respiratory samples suggest that the
viruses are continuously secreted from infected gastrointest-
inal cells (9). The period of viral secretion from pediatric fecesDOI: 10.6061/clinics/2020/e1909
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is longer than in adults (10). These observations suggest that
the inflamed gut of adults and children with IBD could be
more susceptible to infection with SARS-CoV-2 because it is a
doorway for the virus (11,12).
As the COVID-19 outbreak is rapidly evolving, IBD
specialists from all over the world have been challenged to
face the pandemic and address the specific issues of their
patients, particularly regarding the risk of infection and
immunosuppressive treatment. This review aims to sum-
marize the best available evidence and expert opinion in the
field of IBD and COVID-19 outbreak.
What is the risk of COVID-19 in the IBD population?
IBD treatment often involves the prescription of immuno-
suppressants and IBD patients are likely to be more sus-
ceptible to infection, depending on the medications in use.
As the outbreak became a rapidly spreading pandemic,
several centers around the world have raised concerns that
immunocompromised patients may be at increased risk of
developing SARS-CoV-2 infection or severe respiratory
disease (13).
In general, IBD patients taking immunomodulators may
be more susceptible to infection, especially in combination
with biologics, mainly anti-TNF agents. In addition, malnu-
trition, comorbidities, older age, previous history of serious
infections, and underlying IBD activity may also be risk
factors for infections (14,15).
Previous studies have demonstrated that clinically active
IBD and exposure to thiopurines increase the risk of viral
infections (16,17). However, unlike other viruses (Influenza,
Herpes, Cytomegalovirus, Adenovirus, Rhinovirus, Noro-
virus, and Respiratory Syncytial Virus), coronaviruses have
not been shown to cause more severe disease in immuno-
suppressed patients (13,15,17).
So far, there is an international consensus that patients
with IBD are not at greater risk of infection with SARS-CoV-2
than the general population, although it is uncertain whether
active inflammation increases the risk of getting SARS-CoV-
2. It is also uncertain if IBD patients infected with SARS-
CoV-2 have a higher risk of developing COVID-19 or higher
rate of complications or mortality resulting from the disease,
although data regarding immunosuppressed patients and
SARS-CoV-2 infection are very scarce (14).
Guan et al. did not observe the use of immunomodulators
as a risk factor for serious diseases in 1,099 patients in China
(18). As of April 3, 2020, 12 deaths (9 male) were reported
among the 275 patients with IBD and COVID-19 in the inter-
national Surveillance Epidemiology of Coronavirus Under
Research Exclusion (SECURE)-IBD database. Of those, three
patients were younger than 65 years old, and all received
treatment with more than one immunosuppressant (steroid+
JAK inhibitor; adalimumab+methotrexate; adalimumab+
azathioprine+steroid) (19). Nevertheless, these cases should
be interpreted with caution since many cases with mild
disease were not tested for COVID-19.
In a coordinated initiative from the British Society of
Gastroenterology (BSG) and Crohn’s and Colitis UK associa-
tion, specific guidance was provided for IBD patients
according to their risk depending on the medications in
use, age, and other risk factors. Through a decision tree,
patients are stratified according to highest, moderate, or
lowest risk of serious complications from COVID-19. Patients
at the highest risk are those who either have a comorbidity
(respiratory, cardiac, hypertension, or diabetes mellitus), those
over 70 years old and on any immunosuppressant therapy for
IBD, those of any age that are receivingX20 mg prednisolone,
new induction therapy with biologics and immunomodulators
(combination therapy) within 6 weeks, those with moderate
to severe active disease or short gut syndrome, and patients
requiring parenteral nutrition. Patients receiving biological
therapy, thiopurines, calcineurin inhibitors, JAK inhibitors,
or combination therapy are stratified as at moderate risk
and the remaining IBD patients as at the lowest risk. Patients
at the highest risk are required to self-isolate, while patients
at moderate or lowest risk should follow strict or general
populace social distancing, respectively (20).
In our center, we followed BSG recommendations regard-
ing risk stratification, although we also considered patients
subjected to IBD surgical procedures within 30 days at
highest risk of serious complications of COVID-19. A brief
summary of specific recommendations provided by us to the
patients according to their risk is described in Table 1.
General recommendations and strategies to
minimize exposure to the virus
For the past month, emerging evidence has guided an
optimized approach to prevent coronavirus infection in IBD
patients to assure the safety of ongoing treatment.
Similar to the general population, IBD patients were advi-
sed to stay at home, maintain proper distance while talking,
wash hands with soap or alcohol-based sanitizer, and avoid
touching facial mucosa (Table 1).
Our institute, the largest in Latin America, has implemen-
ted a massive structural plan to evacuate wards, equip
intensive care units, and to provide sufficient beds for
patients diagnosed with COVID-19 infection. These institu-
tional rearrangements have challenged our IBD team and a
specific approach to maintain IBD care during the pandemic
was needed. A summary of measures set to adapt IBD care is
described in Table 2.
In the gastroenterology department, hospitalized IBD
patients were reallocated to an isolated building with spe-
cialized medical staff, which has minimized exposure to the
virus.
In our outpatient clinic, the great majority of appointments
were rescheduled. Although a formal tele-health system was
not available, medical staff closely monitored patients with
severe active disease that required corticosteroids or were
being treated with combination therapy via telephone calls.
At this moment, laboratory tests are strictly limited, and the
endoscopy unit has only been attending to urgent cases,
according to the recommendations in the guidelines (11).
Therefore, whenever deemed necessary, ileocolonoscopy was
replaced by fecal calprotectin.
At our infusion center, the staff requested us to select
patients that could have their infusion postponed for 1 or
2 weeks in order to make more space available for the
rearrangement of seats. We used patients in deep clinical and
endoscopic remission at the last outpatient clinic assessment
as the main criteria for the rescheduling of infusions. In
the course of infusions, a distance of approximately 1.5 m
between seats was considered safe and no accompanying
person was permitted. Although we acknowledged that the
use of surgical masks for immunodeficient patients is indi-
cated, it was not always available. Thus, a screening protocol
with an objective interview was implemented prior to
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admission to systematically assess for acute respiratory tract
symptoms, such as cough, dyspnea, or fever, among both
IBD patients and their contacts. Asymptomatic patients recei-
ved IV infusions as planned, while those with highly sus-
picious coronavirus infection were referred to the emergency
room. In cases where initiation of biologics was extremely
necessary, and when it was feasible, preference for those
biologics that could be offered subcutaneously, at home,
instead of intravenously, which would require an infusion
center, was recommended.
The association of malnourishment and the risk of infec-
tions is well described in IBD literature (23,24). Hypoalbu-
minemia is considered a systemic inflammatory marker and
is present in one-fifth of IBD patients (25,26). In the present
context of the COVID-19 pandemic, social isolation could
negatively impact the patient’s access to healthy foods or
dietary habits resulting in ensuing nutritional deficits. Thus,
we have recommended a balanced diet with four to six small
meals a day and adequate hydration. All patients were also
encouraged to quit smoking.
In addition, IBD patients were advised to update general
immunization schedules, particularly the influenza vaccina-
tion, as routinely recommended by the European Crohn’s
and Colitis Organization (ECCO) guidelines (27,28).
Several studies have examined the role of vitamin supple-
mentation to control viral replication (29). Despite the lack of
randomized controlled trials in this scenario, we have kept
our IBD patients on vitamin D and iron replacement, if iron-
deficiency anemia was detected.
Table 2 - Measures to adapt IBD care during the pandemic.
Inpatient clinic
- Wards of main building evacuated to provide care specifically for
patients with COVID-19
- Hospitalized IBD patients relocated to an isolated building,
minimizing exposure to the virus
Outpatient clinic
- Most visits rescheduled
- Medical staff monitored patients with active disease or flare with
telephone calls
- Laboratory tests strictly limited
- Colonoscopy replaced with fecal calprotectin
Infusion center
- No accompanying person permitted
- Rearrangement of seats allowing a distance of approximately 1.5 m
in between
- Surgical masks when available
- Pre-admission screening protocol to assess for acute respiratory tract
symptoms among IBD patients and their contacts
- Selection of patients that could have their infusion postponed for
1 or 2 week to let more space available for rearrangements of seats
(deep clinical and endoscopic remission
Table 1 - Recommendations for IBD patients according to their risk level.
Highest risk Moderate risk Lowest risk
- Stay home at all times
- Don’t leave home to buy food,
medicine or exercise
- You must attend for infusions
(only time you can come out)
- Stay at least 2 meters (3 steps)
from other people in your home
whenever possible)
- In case of delivery of food and
medicine at your home, ask the
courier to leave it outside the
house
- Make sure that anyone who enters
your home washes their hands
with soap and water for
20 seconds
- Do not receive visitors, including
friends and family, unless you
need their help
- Do not stop taking any
medications without talking to
your doctor
- Avoid contact with people who are showing
symptoms of COVID-19
- Avoid using public transport whenever
possible
- Work from home whenever possible
- Avoid crowds and public spaces
- Avoid meetings with friends and family
- Use phone services or virtual technology to
contact your doctor or other essential services
For all group risks*:
- Wash hands thoroughly with soap and
water, for at least 20 seconds, frequently
- Use 70% alcohol gel on your hands if soap
and water are not available
- Avoid touching eyes, nose and mouth
- Clean objects and surfaces that you
frequently touch (such as door handles
and phones) with any cleaning product
- Everyone should stay home to help
prevent the spread of the virus
- Avoid using public toilets+
Leave home for very limited purposes**:
 Buying food and medication,
 Exercise once a day, such as running,
walking or cycling - alone or with a
member of your family.
 Donate blood or help a vulnerable person.
 Travel for professional purposes, but only
if strictly necessary
** Even when performing these activities, you
should minimize the time spent away from
home and ensure that you are 2 meters
away from anyone.
*Recommendations given by the World Health Organization to the general population (21,22.)
+The presence of viral RNA in fecal samples has been reported, thus implicating a potential route of fecal-oral transmission (19).
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Management of IBD medications during the
pandemic and potential COVID-19 infection
At the present time, it does not seem appropriate to
recommend discontinuing immunosuppressant treatment in
patients with IBD (11). There is a risk of reactivation of the
disease for those patients who stop their treatment, and
active inflammation is associated with an increased risk of
hospitalization, surgery, infection, and exposure to steroids
(which should be avoided in the context of COVID-19)
(20,30).
The use of non-hormonal anti-inflammatory drugs should
be contraindicated because of their association with adverse
outcomes in other viral respiratory infections and their
potential role as a trigger for the reactivation of IBD (14).
Table 3 - Therapy-specific considerations for inflammatory bowel disease patients (UC=ulcerative colitis; CD=Crohn’s disease).
Adults Children
Aminosalicylate acid derivatives (5-ASA)
No evidence of increased risk of COVID-19 infection.
Do not stop if infected with COVID-19.
Oral dose of 5-ASA should be optimized for maximum
dose +/- topical (rectal), to avoid starting immunosuppressants,
if possible, in patients with UC.
No evidence of increased risk of COVID-19 infection.
Should never be suspended.
Corticosteroids
Safety during COVID-19 infection is unclear.
Corticosteroids can be used to treat disease relapses in a low
dose and short period as possible.
Tapering as soon as possible.
Budesonide can be used for patients with ileo-caecal CD.
Budesonide MMX can be used for UC patients (not available in Brazil).
Safety during COVID-19 infection is unclear.
Systemic corticosteroid does not confer clinical benefit.
Corticosteroids can be used to treat disease relapses in
a low dose and short period as possible.
Tapering as soon as possible.
Immunomodulators (Thiopurines and Methotrexate)**
No evidence of increased risk of COVID-19 infection.
Associated with the risk of serious viral infection (other than COVID-19).
Initiation of monotherapy is not advised.
Maintenance of combination therapy with biologics should be
discussed individually.
Consider stop:
- Stable disease, especially when deep remission.
- Elderly patients and/or those with significant comorbidities,
in sustained remission.
- Stop if signs and symptoms suggestive of COVID-19 develop.
No evidence of increased risk of COVID-19 infection.
Immunomodulators have been prescribed without changes
in doses or intervals in almost all children.
- SARS-CoV2 Positive and Negative (symptomatic):
Recommend suspending immunosuppressive treatment
during an acute febrile illness until fever subsides and the
child returns to normal health.
- SARS-CoV-2 Positive (asymptomatic): Decision of therapeutic
changes should be individualized.
Anti-TNF therapy*
No evidence of increased risk of COVID-19 infection.
Maintain dose and infusion interval.
Consider initiation in monotherapy (adalimumab or certolizumab,
as SQ, may be administered at home).
Stop if develop signs and symptoms suggestive of COVID-19.
Only Infliximab and Adalimumab approved.z
No evidence of increased risk of COVID-19 infection.
Maintain dose and infusion interval.#
Switching from infliximab to adalimumab should be
discouraged in stable patients.
Anti-IL-12/23p40 therapy (Ustekinumab)*
No evidence of increased risk of COVID-19 infection.
Monotherapy is advised.
General good safety profile.
Stop if develop signs and symptoms suggestive of COVID-19.
Not approved in children.
Anti-a4b7 integrin therapy (Vedolizumab)
No evidence of increased risk of COVID-19 infection.
Monotherapy is advised.
General good safety profile.
Stop if develop signs and symptoms suggestive of COVID-19.
Not approved in children.
Janus Kinase inhibitors (tofacitinib)
No evidence of increased risk of COVID-19 infection however,
tend to inhibit the immune response to viral infections.
Initiation is not advised.
Maintain therapy without increasing the dose.
Stop if develop signs and symptoms suggestive of COVID-19.
Not approved in children.
* Patients who are going to start biological therapy, the subcutaneous route may be preferable on this occasion to avoid visits to clinics or hospitals.
** Stopping this therapy will not have short-term benefits, as these agents take months to clear immunosuppressing effect.
zBiologic plus immunomodulator in stable patients may increase risk over monotherapy but there is no specific evidence.
#Infusion facilities.
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To date, there are no formal evidence-based recommenda-
tions from clinical societies or governments for immunosup-
pressed patients, like those with IBD. Table 3 summarizes the
therapy-specific considerations for IBD patients based mainly
on expert opinions and must be interpreted in a patient-
specific context. These recommendations can be modified and
updated as new evidence emerges (14,20).
In general, a patient with moderate to severely active
Crohn’s disease or ulcerative colitis should be treated with
the same therapies that would be chosen, regardless of the
COVID-19 pandemic (14).
In an asymptomatic IBD patient who has tested positive
for SARS-CoV-2 and whose treatment has been discontinued,
IBD drugs can be restarted after 14 days (assuming they have
not developed COVID-19) (14).
In cases of the occurrence of signs and symptoms suggestive
of COVID-19, the patient must immediately communicate
with the healthcare team. In this context, it is recommended
to pause immunosuppressant therapy until the infection
resolves. The therapy can be resumed after complete resolu-
tion of the symptoms of COVID-19 or, ideally, after two
negative PCR tests of the nasopharyngeal swab, collected with
a more than 24-h interval between them (this strategy is not
currently feasible in Brazil, where there is a shortage of tests
for coronavirus) (14,20).
IBD surgery in the context of the COVID-19
pandemic
The novel coronavirus has created a new dilemma for
surgeons worldwide. While many patients await surgery, the
risks of developing severe pulmonary infection and pro-
longed hospitalization are concerning. This is particularly
critical for IBD patients, who are immunosuppressed by both
the nature of the disease and commonly used medications,
in addition to nutritional deficits. Surgical care in this context
may add additional morbidity.
The main goal at this moment is to ensure the safety of
patients and health care workers. Current recommendations
are based largely on experts’ opinions and may change rapidly
as the outbreak is expected to escalate over the next weeks. A
recent report from Wuhan, China, describes the outcomes of 34
patients that underwent elective surgical procedures during the
COVID-19 incubation period in the early phase of the outbreak.
All patients developed COVID-19 pneumonia shortly after
surgery, 15 (44.1%) patients required admission to the intensive
care unit and seven patients (20.5%) died (31).
Therefore, it is highly recommended by most surgical socie-
ties around the world to postpone all elective surgeries and
endoscopic procedures, aiming to protect patients and sur-
geons and also to minimize the use of necessary resources,
such as hospital beds and personal protective equipment
(PPE) (32,33). Regarding the surgical procedure, there is
concern for the aerosolization of the SARS-CoV-2 virus in
minimally invasive procedures, although there is no robust
evidence. This could also be the case with electrocautery use
during open surgery. Strict use of PPE according to local
practice is advisable, which includes an N95 mask and face
shield protection. Negative pressure surgical rooms should be
used if available and for laparoscopic surgery, a smoke
evacuation system is advisable. Additionally, only essential
staff should take part in the surgery.
Before embarking upon the operating room, different
aspects should be considered, such as the risk of SARS-CoV-2
infection at your facility, expected length of stay, and possible
surgical complications and other clinical comorbidities that
may add additional morbidity/mortality. If surgical treatment
is deemed necessary, informed consent should be obtained
addressing the risk of SARS-CoV-2 infection. Ideally, surgical
patients should be tested pre-operatively for COVID-19,
although this strategy is not possible in our institution where
just symptomatic patients are being tested.
There is no precise advice regarding which IBD patients
would most likely benefit from surgery in this context since IBD
societies around the world have not specifically addressed
surgical care. Therefore, medical judgment remains essential.
Our group considers patients with anorectal septic
complications (i.e. perianal abscess due to Crohn’s disease),
acute peritonitis, bowel obstruction, severe/toxic colitis
(toxic megacolon), and gastrointestinal hemorrhage who fail
conservative treatment are possible surgical candidates during
the pandemic, but cases should be analyzed on an individual
basis. Advanced colorectal malignancy that may progress to
unresectable disease can also be considered for surgery. When
available, minimally invasive strategies such as percutaneous
drainage of an abscess may be a good strategy.
Considerations regarding the pediatric IBD
population
IBD in children often presents with more extensive and
severe disease than adults. Therefore, SARS-CoV-2 infection
with digestive symptoms is of particular concern in pediatric
IBD (PIBD) patients. As of April 3rd, 2020, eleven children
(younger than 19 years) have been reported to have SARS-
CoV-2 infection by SECURE-IBD from a total of 275 patients.
No cases were from Brazil. Only one patient was younger
than 9 years; all cases were outpatients and no deaths were
reported. Some questions arose: are PIBD patients at increa-
sed risk of SARS-CoV-2 infection? Is the infection in PIBD
more severe than in adults? Should treatment be delayed or
discontinued during the infection?
A recent paper from the Pediatric IBD PORTO Group of
ESPGHAN outlined key information about children with
IBD and SARS-CoV-2 infection and provided clear gui-
dance on how to proceed (12). Chinese and Korean pedia-
tric GI specialists reported 272 cases in children with IBD
and SARS-CoV-2 infection during the pandemic while
Europeans reported 8 PIBD patients (14-19 years) with
COVID-19 from the PORTO-IBD group and SECURE-IBD
database.
The Chinese experience reported 917 children with con-
firmed COVID-19 infections, and none of them had the diag-
nosis of IBD. In Korea, from 8,413 children with confirmed
COVID-19 diagnosis, 272 (3.2%) had IBD and almost all
(99.3%) continued IBD treatment. Among 4.8% of children
that postponed biological infusion, 23% experienced an IBD
flare.
In Europe, from the total of eight patients, seven were from
the Porto-IBD and one adolescent (17 years) was from the
SECURE-IBD database. The majority had Crohn’s disease and
most patients were in deep remission or had a moderate
disease activity index, and only one had cardiovascular disease.
Almost all patients had a confirmed diagnosis of COVID-19
with mild symptoms of fever, cough, fatigue, and interestingly,
none of the eight patients had diarrhea.
This initial global experience may help many PIBD centers
in the world implement actions during the COVID-19
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pandemic. Nevertheless, many questions about children and
PIBD COVID-19 infections remain unanswered. The main
recommendations pertaining to treatment of PIBD during the
COVID-19 pandemic are listed in Table 3.
’ CONCLUSION
In the current COVID-19 pandemic, the search for safety
information and guidance is critical. IBD patients have
a potentially higher risk of complications of COVID-19 due
to the chronic illness itself, and mainly, the use of immu-
nosuppressant treatments. Facing these challenging cir-
cumstances, our group has adapted IBD care by resetting
priorities, providing appropriate information for patients,
and assuring continuity of treatments. Finally, it is of para-
mount importance to remember that in developing coun-
tries, a significant part of the population lives in precarious
conditions, with crowding, slum dwelling, and lack of basic
sanitation, among other unique features, which deserve
special attention from health authorities and effective
adaptations. It turns out that, in this scenario, especially
in the case of IBD patients, treatment individualization is
mandatory, and the benefits and disadvantages should
always be taken into account.
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